Literature DB >> 14499782

High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study.

G Midhagen1, C Hallert.   

Abstract

OBJECTIVES: The aim of this study was to determine the occurrence of GI symptoms in adults with celiac disease (CD) treated with a gluten-free diet for several years.
METHODS: We studied a cohort of adults with CD (n = 51; 59% women) aged 45-64 yr and proved to be in remission after 8-12 yr of treatment. They were examined by the GI Symptom Rating Scale, which comprises five syndromes: indigestion, diarrhea, constipation, abdominal pain, and reflux. A general population sample (n = 182; 57% women) of same age served as controls.
RESULTS: Subjects with CD reported significantly more GI symptoms than the general population sample, as assessed by the GI Symptom Rating Scale total score (p < 0.01). This was particularly true for women with CD who scored worse than female controls for all syndromes on the GI Symptom Rating Scale. By contrast, the men with CD reported no more symptoms than male controls. The women with CD showed generally more complaints than the men with CD did, notably within indigestion, constipation, and abdominal pain, corresponding to a 2-fold higher rate of GI symptoms (60% vs 29%; p < 0.04).
CONCLUSIONS: Adult CD patients on a gluten-free diet for several years experienced significantly more GI symptoms than the general population sample. This may have some of its origin in the composition of a gluten-free diet. The symptoms were more pronounced in the women. This may raise questions of an association with their subjective health status, which has been shown to be lower than in men with CD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499782     DOI: 10.1111/j.1572-0241.2003.07632.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  22 in total

1.  A review of rifaximin and bacterial overgrowth in poorly responsive celiac disease.

Authors:  Matthew S Chang; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

2.  The Canadian Celiac Health Survey.

Authors:  Ann Cranney; Marion Zarkadas; Ian D Graham; J Decker Butzner; Mohsin Rashid; Ralph Warren; Mavis Molloy; Shelley Case; Vernon Burrows; Connie Switzer
Journal:  Dig Dis Sci       Date:  2007-02-22       Impact factor: 3.199

Review 3.  Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions.

Authors:  Lena Ohman; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01-26       Impact factor: 46.802

Review 4.  Screening for celiac disease in the general population and in high-risk groups.

Authors:  Jonas F Ludvigsson; Timothy R Card; Katri Kaukinen; Julio Bai; Fabiana Zingone; David S Sanders; Joseph A Murray
Journal:  United European Gastroenterol J       Date:  2015-04       Impact factor: 4.623

5.  Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.

Authors:  Matthew Siegel; Mitchell E Garber; Andrew G Spencer; Wendy Botwick; Pawan Kumar; Robert N Williams; Kenji Kozuka; Revati Shreeniwas; Vijaya Pratha; Daniel C Adelman
Journal:  Dig Dis Sci       Date:  2011-09-23       Impact factor: 3.199

Review 6.  The mucosal immune system: master regulator of bidirectional gut-brain communications.

Authors:  Nick Powell; Marjorie M Walker; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-01-18       Impact factor: 46.802

7.  Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease.

Authors:  Matthew S Chang; Maria T Minaya; Jianfeng Cheng; Bradley A Connor; Suzanne K Lewis; Peter H R Green
Journal:  Dig Dis Sci       Date:  2011-06-07       Impact factor: 3.199

Review 8.  The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet.

Authors:  Christopher S McAllister; Martin F Kagnoff
Journal:  Semin Immunopathol       Date:  2012-06-07       Impact factor: 9.623

Review 9.  Immunopathogenesis and therapeutic approaches in pediatric celiac disease.

Authors:  Shreya Agarwal; Oormila Kovilam; Terence L Zach; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-04-01       Impact factor: 4.473

Review 10.  The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate.

Authors:  Shahryar Khaleghi; Josephine M Ju; Abhinav Lamba; Joseph A Murray
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.